Startup · $28m raised
Melbourne, VIC
Programs: Brandon BioCatalyst (CUREator)
Every investor coverage indicates participated in a round Azura Ophthalmics raised.
| Investor | Rounds | Invested |
|---|---|---|
| TPG Biotech | Unnamed stage | - |
| OrbiMed | Unnamed stage | - |
| Medical Research Commercialisation Fund (MRCF) | Unnamed stage | - |
| Gannet Capital | Unnamed stage | - |
| Brandon BioCatalyst | Accelerator · Grant | - |
Investors whose own portfolio pages list Azura Ophthalmics, even though we haven't found any coverage of the round yet.
| Investor | Listed on |
|---|---|
| Brandon Capital | its portfolio page ↗ |
Companies Azura Ophthalmics acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
Stories naming Azura Ophthalmics. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Eye-drug developer Azura Ophthalmics, working from Melbourne and Tel Aviv, has assembled a seven-member scientific advisory board of ophthalmology specialists to guide clinical development of its lead candidate AZR-MD-001.
Azura Ophthalmics won a CUREator grant to fund a two-stage study of its AZR-MD-001 candidate for contact lens discomfort, extending pilot research conducted with UNSW; the incubator program is run by Brandon BioCatalyst.
Brandon BioCatalyst's CUREator incubator names its first-round awardees, distributing government-backed funding across 23 Australian life science companies working on treatments from schizophrenia to diabetes, with round two applications now open.
The CUREator incubator, run by Brandon BioCatalist's partner organisation, names its first-round awardees, distributing government-backed grant funding across 23 Australian life science companies developing treatments for diseases including diabetes, cancer and COPD.
Eye-disease drug developer Azura Ophthalmics has appointed healthcare biotech veteran Steven Altschuler, a Ziff Capital Partners managing director and Spark Therapeutics co-founder, as chair of its board.
Brandon Capital's blog republishes an AFR report on Azura Ophthalmics' encouraging phase 2 dry-eye results, recalling the Israel-founded biotech's US$38 million raised, among it a US$16 million round that Brandon Capital's fund co-led.
Azura Ophthalmics reports positive phase two results for its dry eye ointment and moves toward registration studies; the Brandon Capital-backed biotech has raised US$38 million, including a US$16 million round co-led by MRCF.
Eye-disease drug developer Azura Ophthalmics announced a $28 million round from existing backers including MRCF, OrbiMed, TPG Biotech and Ganot Capital, funding registration studies of its dry eye treatment candidate.
Also Brandon BioCatalyst portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio